Gilead files for filgotinib in Japan; Alzheimer's flop forces some painful next steps at Neurotrope
→ Gilead has been right on the heels of its rival AbbVie with its JAK-inhibitor filgotinib. The company has now submitted an NDA …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
